N-[3-(3-bromo-imidazo[1,2-b]pyridazin-7-yl)phenyl]methanesulfonamide | 1107655-37-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-[3-(3-bromo-imidazo[1,2-b]pyridazin-7-yl)phenyl]methanesulfonamide
• 英文别名: N-[3-(3-bromoimidazo[1,2-b]pyridazin-7-yl)phenyl]methanesulfonamide
• CAS: 1107655-37-7
• 化学式: C₁₃H₁₁BrN₄O₂S
• 分子量: 367.226
• InChiKey: GCHAUIVJGOYLLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  84.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• ORGANIC COMPOUNDS
  申请人：Lizos Dimitrios

  公开号：US20100204235A1

  公开（公告）日：2010-08-12

  Compounds of formula I in free or salt or solvate form, where R 1 , R 2 and R 5 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK- 5 and/or ALK- 4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式I的化合物，以自由形式、盐形式或溶剂合物形式存在，其中R1、R2和R5的含义如规范中所示，可用于治疗由ALK-5和/或ALK-4受体介导的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] SULFONAMIDES AS TRPM8 MODULATORS<br/>[FR] SULFONAMIDES COMME MODULATEURS TRPM8
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009012430A1

  公开（公告）日：2009-01-22

  ABSTRACT Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein A, B, G, Y, R1, R2, R3, and R4 are defined herein.

  摘要：本文披露了用于治疗各种疾病、综合症、症状和疾病的化合物、组合物和方法，包括疼痛。这些化合物由以下公式（I）表示：其中A、B、G、Y、R1、R2、R3和R4在此处定义。
• SULFONAMIDES AS TRPM8 MODULATORS
  申请人：Janssen Pharmaceutica, N.V.

  公开号：EP2183239A1

  公开（公告）日：2010-05-12
• US8143253B2
  申请人：——

  公开号：US8143253B2

  公开（公告）日：2012-03-27
• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSÉS ORGANIQUES
  申请人：NOVARTIS AG

  公开号：WO2009013335A1

  公开（公告）日：2009-01-29

  Compounds of formula (I) in free or salt or solvate form, where R1, R2 and R5 have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.